XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.66

+2.8%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BostonView who wrote (11277)	8/17/1999 12:29:00 AM
From: Kushi Kullar	Read Replies (1) of 17367

The quote below seems to indicate they are scheduling a meeting with FDA to present data. Bloomberg seemed to imply that they had been asked for more analysis. While all this may be technically accurate in some arcane way it leaves me with little confidence in this crew. "The past few months have been particularly eventful," said Jack Castello, Chairman, President and CEO of XOMA. "After concluding accrual in the meningococcemia trial in May, we have made a preliminary analysis and are scheduling a meeting with the FDA to present data prior to filing a BLA. We have also concluded several other important business transactions that collectively strengthen the Company's financial position and improve our risk profile. These include expanding our hu1124 relationship with Genentech, signing our first BPI product development partnership with Allergan and, most recently, closing a $17.4 million equity financing with new institutional investors."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next